Ones To Watch News
Refine Search
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
French clinical-stage biotech Abivax has appointed Marc de Garidel as chief executive (CEO) and interim board chairman of the company, effective May 5, 2023. 6 April 2023
Pharmaceutical
US immunology focussed biotech Immunic saw its shares soar more than 23% to $1.80 in early trading today, as it reported positive data from the maintenance phase of its Phase IIb CALDOSE-1 trial of its lead asset, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC). 5 April 2023
Biotechnology
The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the use of Germany-headquartered clinical-stage biotech InflaRx Gohibic (vilobelimab) injection. 5 April 2023
Pharmaceutical
A Citizen Petition (CP) has been filed on behalf of Swiss biotech Idorsia Pharmaceuticals, urging the USA’s Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review of evidence from available data, including post-marketing surveillance data. 5 April 2023
Biotechnology
The US Food and Drug Administration (FDA) has placed a partial clinical hold on all trials of Gossamer Bio’s GB5121, in response to serious adverse events that have been observed in the Phase Ib/II STAR-CNS study, including atrial fibrillation, a sudden death event and a fatal intracranial hemorrhage. 5 April 2023
Biotechnology
Privately-held US precision oncology company Scorpion Therapeutics has announced a deal with French drugmaker Pierre Fabre. 4 April 2023
Pharmaceutical
Dermatology company Botanix Pharmaceuticals has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide. 4 April 2023
Biotechnology
OncoSec Medical closed down almost 50% on Monday and fell a further 6% to $1.22 pre-market today, after the company announced primary endpoint data from the Phase II KEYNOTE-695 clinical trial that missed its goals. 4 April 2023
Biotechnology
Continuing to invest the massive profits generated from its COVID-19 vaccine Comirnaty success, German biotech BioNTech has signed up for another oncology collaboration. 3 April 2023
Pharmaceutical
Shares in Sweden’s Asarina Pharma looked set to close more than 2% higher based on results from its Phase IIa study of the endogenous neurosteroid sepranolone for the treatment of Tourette syndrome. 3 April 2023
Pharmaceutical
Karim Mikhail is to resign as president and chief executive of Amarin Corp, the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing. 3 April 2023
Biotechnology
French oncology focussed biotech firm Innate Pharma’s shares were up 16.6% at 3.12 euros in early trading today, as it revealed an exclusive license agreement with Japan’s Takeda (TYO: 4502) 3 April 2023
Biotechnology
China’s Junshi Biosciences has entered an agreement with Rxilient Biotech (a portfolio company of Legend Capital), to form a joint venture to develop and commercialize its cancer drug toripalimab in Southeast Asia. 31 March 2023
Biotechnology
A new oncology-focused spinout will be launched by Citius Pharmaceuticals, with the goal of developing the immuno-oncology asset I/ONTAK. 31 March 2023
Biotechnology
US biotech Scynexis’ shares were up more than 130% in pre-market trading after it revealed the signing of an exclusive licence agreement with UK pharma major GSK for Brexafemme (ibrexafungerp tablets). 30 March 2023
Biotechnology
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics revealed today that it has entered a collaboration agreement with Japan’s Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases. 30 March 2023
Biotechnology
The US Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase I/II VELA trial of BLU-222, said the drugs developer, Blueprint Medicines, sending the US biotech’s shares up 4% to $42.57. 30 March 2023
Biotechnology
A short delay to bluebird bio’s US regulatory submission for lovo-cel (lovotibeglogene autotemcel) appears to have spooked investors, with shares in the company falling by a quarter. 30 March 2023
Pharmaceutical
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
Biotechnology
Shares US biotech Bicycle Therapeutics closed up more than 11% at $22.40 yesterday, after it revealed a licensing deal that could earn it as much as $1.7 billion. 29 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze